Table 2.
Comparison of baseline data between NAFLD group and non-NAFLD group.
| Parameters | NAFLD group (n=111) | Non-NAFLD group (n=214) | χ2/t value | p value |
|---|---|---|---|---|
| Male [cases (%)] | 62 (56) | 128 (60) | 0.471 | 0.492 |
| Age (years) | 69.3±9.18 | 71.1±8.82 | 1.262 | 0.208 |
| Hypertension [cases (%)] | 60 (54) | 122 (57) | 0.259 | 0.611 |
| Diabetes [cases (%)] | 73 (66) | 101 (47) | 10.132 | 0.001 |
| Coronary heart disease [cases (%)] | 84 (76) | 136 (64) | 4.913 | 0.027 |
| CABG/PCI [cases (%)] | 38 (34) | 34 (16) | 14.265 | <0.001 |
| Smoking [cases (%)] | 80 (72) | 158 (74) | 0.115 | 0.734 |
| Anterior wall myocardial infarction [cases (%)] | 65 (59) | 128 (60) | 0.048 | 0.827 |
| Inferior wall myocardial infarction [cases (%)] | 39 (35) | 71 (33) | 0.125 | 0.724 |
| Right ventricular infarction [cases (%)] | 7 (6) | 15 (7) | 0.057 | 0.811 |
| EF (%) | 40±12 | 51±13 | 2.500 | 0.042 |
| EF <35% [cases (%)] | 50 (45) | 45 (21) | 20.38 | <0.001 |
| Time from onset to visit <8 h [cases (%)] | 91 (82) | 183 (86) | 0.689 | 0.406 |
| Time from onset to visit <12 h [cases (%)] | 101 (91) | 200 (93) | 0.65 | 0.420 |
| Aspirin [cases (%)] | 111 (100) | 212 (99) | 1.044 | 0.307 |
| Clopidogrel [cases (%)] | 109 (98) | 212 (99) | 0.452 | 0.501 |
| β-blocker [cases (%)] | 65 (59) | 128 (60) | 0.048 | 0.827 |
| ACEI [cases (%)] | 98 (88) | 199 (93) | 2.053 | 0.152 |
| Statin [cases (%)] | 110 (99) | 212 (99) | 0.001 | 0.976 |
| Thrombolytic therapy [cases (%)] | 39 (35) | 91 (43) | 1.662 | 0.197 |
| Emergency PCI treatment [cases (%)] | 72 (65) | 123 (57) | 1.662 | 0.197 |
CABG – coronary artery bypass grafting; PCI – percutaneous coronary intervention; EF – ejection fraction in heart; ACEI – angiotensin-converting enzyme inhibitor.